BRAF and cancer: Of those cases in which molecular analysis of cytology specimens revealed a BRAF mutation, 2/14 (14%) proved benign on histology, while 12/14 (86%) were malignant neoplasms: 11/12 (92%) PTC and 1/12 (8%) PTC follicular variant; no follicular or medullar neoplasms were found.